PI3Kδ Regulates the Magnitude of CD8⁺ T Cell Responses after Challenge with *Listeria monocytogenes*

Verity Q. Pearce, Hicham Bouabe, Amy R. MacQueen, Valentina Carbonaro and Klaus Okkenhaug

*J Immunol* published online 26 August 2015
http://www.jimmunol.org/content/early/2015/08/26/jimmunol.1501227

Supplementary Material
http://www.jimmunol.org/content/suppl/2015/08/26/jimmunol.1501227.DCSupplemental

Subscription
Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

Permissions
Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
PI3Kα Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes

Verity Q. Pearce, Hicham Bouabe, Amy R. MacQueen, Valentina Carbonaro, and Klaus Okkenhaug

PI3Ks regulate diverse immune cell functions by transmitting intracellular signals from Ag, costimulatory receptors, and cytokine receptors to control cell division, differentiation, survival, and migration. In this study, we report the effect of inhibiting the p110d subunit of PI3Kα on CD8+ T cell responses to infection with the intracellular bacteria Listeria monocytogenes. A strong dependency on PI3Kα for IFN-γ production by CD8+ T cells in vitro was not recapitulated after Listeria infection in vivo. Inactivation of PI3Kα resulted in enhanced bacterial elimination by the innate immune system. However, the magnitudes of the primary and secondary CD8+ T cell responses were reduced. Moreover, PI3Kα activity was required for CD8+ T cells to provide help to other responding CD8+ cells. These findings identify PI3Kα as a key regulator of CD8+ T cell responses that integrates extrinsic cues, including those from other responding cells, to determine the collective behavior of CD8+ T cell populations responding to infection.

The Journal of Immunology, 2015, 195: 000–000.

Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge CB22 3AT, United Kingdom
ORCID: 0000-0002-9432-4051 (K.O.).
Received for publication May 29, 2015. Accepted for publication July 24, 2015.
This work was supported by Biotechnology and Biological Sciences Research Council Grants BB/F015461/1, BBS/E/B/0000L734, and BBS/E/B/0000C407, and by Wellcome Trust Grant 095691.
Address correspondence and reprint requests to Dr. Klaus Okkenhaug, Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Building 540, Cambridge CB22 3AT, U.K. E-mail: klaus.okkenhaug@babraham.ac.uk
The online version of this article contains supplemental material.

Abbreviations used in this article: EdU, 5-ethynyl-2′-deoxyuridine; Eomes, eomesodermin; FAM-VAD-FMK, FAM–L-valyl–L-alanyl–L-aspartic acid (methyl ester)–fluorescein isothiocyanate; GzmB, granzyme B; Lm-OVA, Listeria monocytogenes expressing OVA; MPEI, memory precursor effector cell; mTOR, mammalian target of rapamycin; PtdIns(3,4,5)P3, phosphatidylinositol(3,4,5)-trisphosphate; SLEC, short-lived effector cell; Teff, effector T cell; Tet, Kb MHC tetramer loaded with SIINFEKL peptide; TF, transcription factor; Tmem, memory T cell; WT, wild-type; YFP, yellow fluorescent protein.

This is an open-access article distributed under the terms of the CC-BY 3.0 Unported license.
naling pathways may contribute more strongly to mTOR activation (7, 8, 25, 26). In turn, mTOR can phosphorylate Akt at Ser273 in a PI3K-independent fashion (22). It is therefore important to appreciate that the PI3Ks regulate signaling proteins in addition to Akt, mTOR, and Foxo TFs and, moreover, that mTOR can be controlled by signaling pathways other than PI3K (5).

The contribution of PI3Kδ to T cell development and function has been studied using p110<sup>δ</sup> mice (in which the p110 subunit of PI3Kδ is inactivated by a point mutation in the catalytic domain), p110<sup>δ</sup>−/− mice, p85-deficient mice, and/or small molecule inhibitors such as IC87114 that selectively inhibit PI3Kδ (5, 27–29). We have found that CD8<sup>+</sup> T cells from p110<sup>δ</sup>−/− mice, or wild-type (WT) T cells stimulated in the presence of Ag in vitro (6). In particular, IFN-γ production was profoundly diminished in p110<sup>δ</sup>−/− CD8<sup>+</sup> T cells and could be suppressed in WT T cells using very low concentrations of IC87114 (6). We and others have also found that the production of cytotoxic proteins produced in CTL granules such as granzyme B (GzmB) and perforin were impaired in vitro, albeit to different extents, when PI3Kδ was inhibited (30, 31). However, mice that lack both the p85α and p85β regulatory subunits in T cells respond normally to infection with mouse hepatitis virus despite impaired PI3K signaling (32). Moreover, we have recently shown that tumors are killed more effectively by the immune system in p110<sup>δ</sup>−/− mice than in WT mice (33). Enhanced killing of tumors was the consequence of inhibition of p110 within regulatory T cells, which helped unleash more potent CD8<sup>+</sup> T cell–dependent antitumor responses (33). These findings imply that CD8<sup>+</sup> T cell function is not entirely abrogated with inactivation of PI3K p110 and compelled us to further investigate the function of PI3K signaling in CD8<sup>+</sup> T cell responses in vivo.

In this study, we have examined the contribution of PI3Kδ to CD8<sup>+</sup> T cell responses to infection with Listeria monocytogenes. L. monocytogenes is a Gram<sup>+</sup> intracellular bacteria widely used to study the dynamics of CD8<sup>+</sup> T cell responses to infection (34). We show that the magnitude of both primary and secondary CD8<sup>+</sup> T cell responses to L. monocytogenes infection is reduced in p110<sup>δ</sup>−/− mice. The altered response was attributable to lack of PI3Kδ activity both intrinsic and extrinsic to responding CD8<sup>+</sup> T cells. Co-transfer studies demonstrated the ability of WT CD8<sup>+</sup> T cells to provide help to p110<sup>δ</sup>−/− T cells, suggesting a role for PI3Kδ in mediating signals required for CD8<sup>+</sup> T cells to support the proliferation of other responding CD8<sup>+</sup> T cells. Unexpectedly, after challenge with L. monocytogenes, p110<sup>δ</sup>−/− CD8<sup>+</sup> T cells produced normal or enhanced levels of IFN-γ, IL-2, and GzmB. Moreover, p110<sup>δ</sup>−/− mice generated normal or enhanced numbers of long-lived memory T cells and raised a robust recall response a year after initial challenge. These findings identify PI3Kδ as a key regulator of CD8<sup>+</sup> T cell responses that integrates extrinsic cues, including from other responding cells, to determine the collective behavior of CD8<sup>+</sup> T cell populations responding to infection.

**Materials and Methods**

**Chemicals**

Chemicals were ordered from Sigma-Aldrich unless otherwise specified. IC87114 was synthesized by Jonathan Clark (Babraham Institute), as described previously (6).

**Bacteria**

*L. monocytogenes*—expressing OVA (Lm-OVA) (35, 36) and its attenuated derivative (ΔactA Lm-OVA) (37) were obtained from Dr. Hao Shen (University of Pennsylvania) or purchased (DMX Bio). Mice were infected i.v. with 1 × 10<sup>6</sup> CFU Lm-OVA or 1 × 10<sup>6</sup> ΔactA Lm-OVA unless otherwise stated. Frozen stocks were thawed at room temperature, diluted in PBS, and injected within 2 h. Actual CFU injected was routinely verified by plating out the stocks that had been thawed for injection.

**Mice**

The following mouse strains used in this study have been described previously and had been backcrossed to the C57BL/6 background for ≥10 generations: p110<sup>δ</sup>−/− (MGI:2385596), OT1 (MGI:3054907), YETI (MGI:3665254) (6, 38–40). All experimental protocols were approved by the Babraham Institute Animal Welfare and Experiment Committee and the Home Office (PPL 80/2248 and 70/7661).

**CD8<sup>+</sup> T cell isolation**

Lymphocyte suspensions were incubated for 30 min at 4°C with 2.5 μg/ml FITC-conjugated anti-CD4a, anti-B220, anti-CD25, anti-CD69, anti-CD49b, and anti-MHC class II Abs. Next, the cells were washed and incubated for 20 min at 4°C with 100 μl anti-FITC MACS magnetic beads (Miltenyi Biotec) per 10<sup>6</sup> cells. Cells were washed again and then applied to a MACS LS column (Miltenyi Biotec), and the flow-through was collected. The resulting cells were >90% CD8<sup>+</sup> , as assessed by flow cytometry.

**Biochemistry**

CD8<sup>+</sup> T cells (3 × 10<sup>6</sup>) were incubated with biotintion Abs against CD3 (145-2C11, 1 μg/ml), anti-CD8 (53-6.7, 10 μg/ml), and anti-CD28 (37.51, 2 μg/ml) (all from BioLegend) on ice for 30 min in 85 μl RPMI 1640 with 0.5% FCS. Cells were washed at 37°C for 2 min before adding 85 μl 1:50 streptavidin (Jackson Immunoresearch Laboratories, 016-000-084) and incubated for 5 min at 37°C. The cells were pelleted by centrifugation and resuspended in 50 μl ice-cold lysis buffer (50 mM HEPES, 150 mM NaCl, 10 mM NaF, 10 mM NaF, 10 mM indocinamide, 5 μl protease inhibitor [Proteoloc], 5 μl EDTA [Proteoloc], 1% [v/v] Nonidet P-40 [BDH]) and incubated for 10 min on ice.

Lysates were centrifuged at 14,800 rpm at 4°C in a microcentrifuge. The supernatant was subsequently mixed with 16.7 μl NuPAGE LDS sample buffer (Life Technologies) and frozen. Lysates were thawed at room temperature and 1 μl M DTT (Life Technologies) was added. The proteins were separated on a 10% Bis-Tris gel (Life Technologies) and transferred to a nitrocellulose membrane (Millipore). The membrane was blocked with 5% milk powder, 15070-063) plus 50 mM 1× PBS, and incubated for 1 h, followed by washing with 1× PBS. The membrane was incubated with the Abs at the following concentrations: anti-CD183 (CXCR3-173, BioLegend), anti–T-bet (eBio4B10), and anti-GzmB (GB12, Invitrogen). The iTag K<sup>+</sup> MHC tetramer loaded with SINFEKL peptide (Tet) was purchased from Beckman Coulter or MBL International. Blood cells were prepared undiluted at 37°C at the temperature for 30 min on ice. Blood cells were incubated with 10 μM Anti-CD42b, 10 μg/ml rB220, 10 μg/ml rCD25, 0.5 μg/ml rCD69, and stained in FACS buffer. The cells were washed and incubated with RBC lysing buffer (Sigma-Aldrich) and then the cells were washed with FACS buffer (PBS containing 2% FCS, 0.1% NaN<sub>3</sub>). Cells from the spleen, bone marrow, and lymph nodes were stained in FACS buffer. Samples were acquired using a BD LSR II flow cytometer. Data were analyzed using FlowJo software (Tree Star, Ashland, OR). For cytokine and GzmB detection, 10<sup>6</sup> lymphocytes from splenic single-cell suspensions of mice that had received 500 OT1 T cells were restimulated with 10 μg/ml OVA323-337, 200 μg/ml anti-IFN-γ (XMG1.2), anti-rGB12, and anti–MHC class II Abs. Next, the cells were washed and fixed with 1% paraformaldehyde in media (RPMI 1640, Life Technologies, no. 21875-034) plus 5% human serum, 1% penicillin/streptomycin (Invitrogen, 15070-063) plus 50 μg/ml 2-ME (Sigma-Aldrich, M3701) in a 96-well plate.
plate (Nunc). For the last 90 min of each time point, cultures were incubated with 10 μg/ml frelseldin A (eBioscience, 15406-51) at 37°C then stained for surface markers, fixed, and permeabilized as previously described before analysis on an LSRFortessa flow cytometer.

Adoptive cell transfers

OVA-specific CD8+ T cells obtained from the lymph nodes of WT OT1 or p110δD910A OT1 mice and purified by magnetic sorting as described above. The number of OT1 cells was calculated based on purity determined by flow cytometry, and indicated numbers of OT1 cells (usually 500) were injected i.v. into the lateral tail vein of mice 18 h prior to infection with Lm-OVA.

5-Ethynyl-2'-deoxyuridine labeling of lymphocytes in vivo

WT and p110δD910A mice were infected i.v. with ~5 × 10^6 CFU ΔactA Lm-OVA. 5-Ethynyl-2'-deoxyuridine (EdU, 250 μg; Life Technologies), dissolved in PBS, was injected i.v. 24 h before culling the mice and collection of organs. Splenocytes were then subjected to cell surface immunostaining, and the incorporation of EdU by DNA was detected by intracellular fluorescent "click" reaction using a Click-iT Plus EdU Alexa Fluor 647 flow cytometry assay kit (Life Technologies), according to the manufacturer's protocol. Briefly, fixed and permeabilized cells were incubated with copper and Alexa Fluor 647 dye–labeled picolyl azide at room temperature for 30–45 min. Copper catalyzes a covalent reaction between picolyl azide and alkyn found in the ethynyl moiety of EdU.

Detection of apoptosis

Splenocytes isolated from WT and p110δD910A mice 5 d after i.v. infection with ~5 × 10^6 CFU ΔactA Lm-OVA were incubated (at ~3–5 × 10^6 cells/well in a 96-well plate) in RPMI 1640, 5% FCS, antibiotics, and 0.75 μM FAM-Δ-valyl-Δ-alanyl-Δ-aspartic acid(methyl ester)-fluoromethyl ketone (FAM-VAD-FMK, Intracellular Technologies) for 3 h at 37°C. Cells were then immunostained and analyzed by a flow cytometer. Dead/necrotic cells (positive for viability dye) were gated out and the percentage of Tet+CD8+ cells labeled with FAM-VAD-FMK was determined.

Results

P13Kδ is required for Akt phosphorylation and IFN-γ production by p110δD910A T cells stimulated in vitro

To test the role of P13Kδ in transducing signals downstream of the TCR and CD28, we stimulated CD8+ T cells purified from WT and p110δD910A mice and monitored phosphorylation of key signaling proteins. Phosphorylation of Akt, Foxo, S6, and Erk was detected in p110δD910A T cells. Moreover, assessment...
of the response to stimulation by PMA demonstrated that whereas the S6K and Erk pathways can be rescued by diacylglycerol-dependent signaling pathways in p110<sup>D910A</sup> cells, Akt and Foxo phosphorylation cannot. Hence, compensatory activation of the Ras-Erk pathway can contribute to mTOR activity independently of PI3K and Akt, consistent with previous results (7, 26). T cells from YETI mice express yellow fluorescent protein (YFP) when the Ifng gene is actively being transcribed (39). To examine the role of PI3K in promoting IFN-γ production more closely, we used cells from YETI mice to monitor the proportion of CD8<sup>+</sup> T cells able to produce IFN-γ after stimulation with anti-CD3, anti-CD28, and IL-12. We found that PI3K<sub>D910A</sub> inactivation reduced YFP and IFN-γ expression in CD8<sup>+</sup> T cells (Fig. 1B). These experiments also showed that during in vitro activation of CD8<sup>+</sup> T cells, T-bet, Eomes, and GzmB expression were lower in p110<sup>D910A</sup>-T cells (Fig. 1B).

**PI3K<sub>D910A</sub> regulates the magnitude of primary and secondary responses to L. monocytogenes infection**

To track CD8<sup>+</sup> T cells responding to infection, we infected mice with a transgenic strain of *L. monocytogenes* that expresses chicken OVA and detected OVA-specific CD8<sup>+</sup> T cells using MHC class I H-2<sup>b</sup> tetramers loaded with OVA<sub>257-264</sub> (SIINFEKL) peptide. The proportions of CD8<sup>+</sup> T cells in the blood that stained positive with the tetramer (Tet<sup>+</sup> CD8<sup>+</sup>) were reduced in p110<sup>D910A</sup> mice (Fig. 2A). This reduction in the proportion of Tet<sup>+</sup>CD8<sup>+</sup> T cells was apparent both at the peak of response as well as among the Tmem that persisted and could be detected before and after subsequent challenges (Fig. 2A). Nevertheless, the p110<sup>D910A</sup> mice did show evidence of CD8<sup>+</sup> Tmem formation, as their secondary responses were more rapid and achieved greater peak magnitude than during their primary response (Fig. 2A). Diminished CD8<sup>+</sup> T cell responses could either be due to a developmental defect that occurs as a result of a congenital lack of p110<sup>D910A</sup> activity in p110<sup>D910A</sup> mice, or due to an acute requirement for PI3K<sub>D910A</sub> activity during T cell activation in vivo. To distinguish between these, we treated WT mice with IC87114 and infected them with Lm-OVA. IC87114 caused a similar defect in the primary response observed in young p110<sup>D910A</sup> mice (Fig. 3A, 3C). However, the numbers of MPECs responded similarly in magnitude to old WT mice (Fig. 3E). Moreover, both WT and p110<sup>D910A</sup> mice that had been infected when young and then reinfected a year later mounted recall responses of similar magnitude despite the impaired primary response observed in young p110<sup>D910A</sup> mice (Fig. 3E). Hence, the impaired primary and secondary CD8<sup>+</sup> T cell responses in p110<sup>D910A</sup> mice give rise to memory T cells that persist into old age to elicit recall responses that are similar in magnitude to those raised by old WT mice.

**PI3K<sub>D910A</sub> activity within CD8<sup>+</sup> T cell populations is required for optimal expansion**

The reduced primary and recall T cell response in young mice could be a consequence of impaired signaling within CD8<sup>+</sup> T cells or due to factors extrinsic to the responding T cells, such as differences in bacterial load, Ag presentation, or cytokine production by macrophages and dendritic cells and/or paracrine help from other responding or bystander T cell populations. We recovered reduced numbers of *L. monocytogenes* colonies from the spleen of p110<sup>D910A</sup> mice compared with WT mice during the first 4 d postinfection (Fig. 4A). Because p110<sup>D910A</sup> spleens are smaller than WT spleens, we also measured CFU in the liver and found again the counts to be significantly lower in p110<sup>D910A</sup> hosts than in WT hosts, similar to what we found in the spleen (Fig. 4B, 4C). Because *Listeria* clearance happens before *Listeria*-specific CD8<sup>+</sup> T cells can be detected, these findings suggest that PI3K<sub>D910A</sub> inhibition can enhance bacterial clearance by the innate immune system.

We therefore sought to determine whether PI3K<sub>D910A</sub> plays a cell-intrinsic role in regulating the expansion of CD8<sup>+</sup> T cells following
FIGURE 2. Defective primary and secondary CD8+ T cell responses in p110D910A mice. (A) WT or p110D910A mice were infected with Lm-OVA on days 0, 62, and 115 (indicated with arrows) with 10^4 CFU Lm-OVA. The graph shows the percentage of CD8+ T cells in blood samples that were Tet+. n = 5 or 6 per group. Statistical analyses: two-way ANOVA of days 0–15, p = 0.002; days 63–110, p < 0.001; days 116–183, p = 0.0013. Results are representative of two independent experiments. (B) Mice treated with IC87114 via the food from days 21 to 10 and infected on day 0 with Lm-OVA. The number of Tet+CD8+ T cells in the blood were enumerated by flow cytometry; n = 8/group. Statistical analyses: two-way ANOVA, p = 0.049. Results are representative of two independent experiments. (C-E) Number of Tet+CD8+ T cells recovered from blood (cells per μl), spleen (cells per spleen), lymph. (Figure legend continues)
infection in the presence of WT innate immune cells. We started by injecting different numbers of CD45.1 WT or CD45.2 p110D910A Tet−CD8+ T cells expressing the OT1 TCR transgene into WT recipient mice expressing CD45.2 and CD45.1 Ags before infecting recipient mice with Lm-OVA. When 200,000, 1,000, or 500 OT1 T cells were injected, the magnitude of expansion by p110D910A OT1 T cells was reduced compared with WT OT1 T cells (Fig. 5, left panel). Interestingly, however, when 100 OT1 T cells were injected, the difference between the expansion of WT and p110D910A T cell responses was less noticeable (Fig. 5, left panel), indicating that the function of PI3Kδ is dependent on the size of the responding population.

Consistent with previously published results (44), transfer of 200,000 OT1 T cells quenched endogenous T cell responses and this was similar for both genotypes, indicating that the p110D910A T cells could compete effectively with endogenous WT T cells for access to APCs (Fig. 5, right panel). When 500 OT1 T cells were injected, the magnitude of the donor and recipient Tet−CD8+ T cell responses were similar. Hence, to mimic physiological starting populations we injected 500 donor OT1 T cells per recipient before infection with Lm-OVA in subsequent experiments.

To further examine the T cell–intrinsic role for PI3Kδ in CD8+ T cells, we next transferred 500 WT (CD45.2) or p110D910A (CD45.1) OT1 cells into WT (CD45.2 or CD45.1) recipients and infected them with Lm-OVA. Similar to endogenous p110D910A CD8+ responses (Fig. 2), transferred p110D910A OT1 cells generated reduced primary and secondary responses compared with transferred WT OT1 cells (Fig. 6A). After a tertiary challenge, the reduction in magnitude of the p110D910A Tet−CD8+ T cell response was most evident in the blood and spleen (Fig. 6D). We considered whether OT1 T cells could outcompete p110D910A OT1 T cells when coinjected into the same host. Contrary to our expectations, we observed equivalent expansion of p110D910A OT1 and WT OT1 T cells both during the primary and secondary responses (Fig. 6B, 6E). However, when compared directly with coinjected WT T cells, p110D910A T cells showed enhanced accumulation in the lymph nodes and bone marrow, which are organs associated with long-term memory (Fig. 6E). Thus, p110D910A CD8+ T cell populations mediate destructive responses to infection, but components of this defect are rescued by provision of WT OT1 T cells. These findings suggest a role for PI3Kδ in mediating signals required for CD8+ T cells to support the proliferation of other responding cells.

**PI3Kδ activity extrinsic to the responding CD8+ T cells also contributes to their optimal expansion**

The ability of coinjected WT OT1 T cells to provide help for the p110D910A T cells raised the question of whether other host cells also support Ag-specific CD8+ T cell expansion in a PI3Kδ-dependent manner. To address this question, we injected WT OT1 T cells into either WT or p110D910A hosts (Fig. 6C, 6F). When the WT OT1 cells were injected into p110D910A hosts, they showed reduced primary, but normal secondary, immune responses. These data indicate that factors produced by the host environment in a PI3Kδ-dependent manner are required to support the initial activation of CD8+ T cells. In particular, the p110D910A host lymph nodes and bone marrow appeared deficient when it came to supporting the expansion of the transferred T cells (Fig. 6F). Nevertheless, WT OT1 T cells transferred into a p110D910A mouse raised a secondary response of similar magnitude to those injected into a WT host (Fig. 6C). This observation indicates that whatever factor is lacking in p110D910A hosts is not required by Tmem.

The magnitude of the CD8+ T cell response is dependent on effective early in vivo Ag presentation, which in turn depends on bacterial load, as treatment of mice with antibiotics 1–2 d postinfection with *L. monocytogenes* resulted in a reduced CD8+ T cell response (45, 46). Taking into account that p110D910A mice clear *L. monocytogenes* more effectively than do WT mice (Fig. 4), we considered that the reduced WT CD8+ T cell response in a p110D910A host might be a consequence of reduced antigenic load. To test this, we analyzed the expansion of Ag-specific CD8+ T cells using nonreplicating Ag by transferring WT OT1 T cells into WT or p110D910A hosts and immunized the mice with OVA peptide and the TLR2 ligand Pam3CSK4 as an adjuvant (47, 48). p110D910A mice immunized with OVA and Pam3CSK4 supported much lower proliferation of WT OT1 cells than did WT hosts (Supplemental Fig. 2A). Similar results were obtained when mice were immunized with OVA and LPS (a component of the cell wall of Gram− bacteria) (Supplemental Fig. 2B). These results demonstrate that there are PI3Kδ-dependent host factors that are independent of effects on bacterial replication and Ag processing that promote WT CD8+ T cell expansion. The expression of Cxcr3, also known as CD183, favors the differentiation of T effector memory T cells (49). Supplemental Fig. 2C shows that Cxcr3 expression was reduced on Tet−CD8+ T cells isolated from blood, spleen, lymph node, and bone marrow of p110D910A mice infected with Lm-OVA 8 d previously. However, the expression of Cxcr3 did not require PI3Kδ activity within T cells because Cxcr3 expression on WT and p110D910A OT1 cells transferred separately (Supplemental Fig. 2D) or together (Supplemental Fig. 2E) into WT hosts was similar. In contrast, when WT OT1 T cells were transferred into p110D910A hosts, Cxcr3 expression was reduced (Supplemental Fig. 2F). These results further demonstrate the lack of paracrine support for the differentiation of effector CD8+ T cells in p110D910A mice.

p110D910A T cells responding to *Listeria* infection express normal amounts of cytokines and GzmB and do not show reduced DNA synthesis or increased death

A previous study showed that CD8+ T cells are themselves an important source of IL-2 production required for their optimal response to *L. monocytogenes* infections (50). The percentage of p110D910A OT1 T cells that produced IL-2 was similar to that seen with WT OT1 cells, regardless of whether the WT and p110D910A OT1 T cells were injected into separate or into the same WT host (Fig. 7A, 7B). To our surprise, a similar proportion of p110D910A OT1 T cells also produced IFN-γ and GzmB (Fig. 7C–F). The in vitro differentiation assays suggested that IFN-γ production by p110D910A T cells might be delayed rather than completely impaired. We therefore monitored IFN-γ production by Tet−CD8+ T cells 5 d postinfection, which is the earliest a distinct population of OVA-specific T cells could be readily identified. Lm-OVA–infected YETI mice revealed that a similar proportion of WT and p110D910A Tet−CD8+ T cells produced IFN-γ also at this earlier time point (Fig. 7G). We also monitored the rate of cell division by measuring the uptake of the nucleotide analog EdU. Surprisingly, we found similar or slightly increased proportions of Tet−CD8+ p110D910A T cells that incorporated EdU (Fig. 7H) (even though the numbers of Tet−CD8+ p110D910A T cells recovered were
Therefore, the reduced number of Tet+CD8⁺ p110⁶⁹₁₀⁻ T cells does not likely reflect an inability to undergo cell division following antigenic stimulation in vivo. As an alternative explanation for the reduced magnitude of p110⁶⁹₁₀⁻ Tet⁺CD8⁺ T cell expansion, we also considered that the loss of PI3K might increase the proportion of cells that undergo apoptosis. To test this, we measured the incorporation of the fluorescently labeled peptide FAM-VAD-FMK, which binds specifically to activated caspases by WT and p110⁶⁹₁₀⁻ Tet⁺CD8⁺ T cells isolated from mice infected 5 d previously (Fig 7I). However, a lower proportion of p110⁶⁹₁₀⁻ Tet⁺CD8⁺ T cells than WT T cells showed signs of undergoing apoptosis. Hence, the requirement for PI3K by CD8⁺ T cells activated in vitro to produce IFN-γ and GzmB is not shared with p110⁶⁹₁₀⁻ CD8⁺ T cells that respond to L. monocytogenes infection in vivo.

**FIGURE 3.** Intact formation of memory T cells and long-term memory responses in p110⁶⁹₁₀⁻ mice. Tet⁺CD8⁺ T cells in blood, spleen, lymph nodes, and bone marrow 8 d postinfection with Lm-OVA are shown. (A) Representative FACS profiles showing CD127 and KLRG1 expression on WT or p110⁶⁹₁₀⁻ Tet⁺CD8⁺ T cells isolated from the indicated organs 8 d after primary infection with Lm-OVA. (B and C) Graphical representation of CD127highKLRG1low MPECs (B) and CD127⁺KLRG1⁰ SLECs (C) 8 d post infection. n = 6, representative experiment of three. *p < 0.05 by unpaired t test. (D and E) WT or p110⁶⁹₁₀⁻ mice were infected with Lm-OVA on days 0 and 54 and the number of Tet⁺CD8⁺ T cells in the blood was enumerated by flow cytometry. (D) Mice were 9 wk old at the start of experiment. (E) Mice were 70 wk at the start of the experiment. (F) WT or p110⁶⁹₁₀⁻ mice were infected with Lm-OVA on days 0 and 359 and the number of Tet⁺CD8⁺ T cells in the blood was enumerated at regular intervals by flow cytometry. n = 5-6/group. Statistical analyses: two-way ANOVA, days 0–20, p = 0.041; days 363–366, not significantly different. Results are representative of two independent experiments.
Moreover, the CD8+ T cells that are detected several days after infection proliferate normally and do not show increased susceptibility to apoptosis. These data suggest that the signaling lesion that causes impaired expansion of p110\(^{\text{D910A}}\) CD8+ T cells may manifest itself relatively early during the immune response and provide evidence that redundant pathways cooperate with PI3K\(\delta\) to promote cytokine expression and cytolytic function in response to infection in vivo.

**Discussion**

In this study, we have shown that PI3K\(\delta\) controls the magnitude of both primary and secondary CD8+ T cell responses in response to infection with the intracellular bacterial pathogen *L. monocytogenes*. However, inhibition of PI3K\(\delta\) does not prevent the differentiation of naive CD8+ T cells into competent long-lived CD8+ Tmem, nor for Teff to produce IFN-\(\gamma\) and GzmB in response to infection in vivo. The ability of CD8+ T cells to generate a full-magnitude primary response to *L. monocytogenes* infection depends in part on PI3K\(\delta\) activity within responding T cell populations.

Recent work from Hodgkin and colleagues (51) has demonstrated that CD8+ T cells integrate signals from the Ag receptor, costimulatory receptors, and cytokine receptors in a linear manner to determine their “division destiny,” which represents the total number of divisions each cell will undergo before contraction of the immune response. We propose that transduction of antigenic signals is weaker in p110\(^{\text{D910A}}\) T cells, and this has long-term consequences in terms of the magnitude of clonal expansion by limiting the number of CD8+ T cells that will reach their full proliferative capacity, even though a snapshot of T cells responding to the Ag (several days after infection) revealed unperturbed proliferation. Possible mechanisms that might explain such reduced proliferative capacity after initial activation may include fewer cells that respond to *L. monocytogenes*, delayed or sustained first divisions, or selective loss of daughter cells after the first division. We are currently analyzing the division of transferred T cells during the first 24–48 h postinfection to evaluate these possibilities. It is also possible that aberrant expression of homing receptors such as CD62L and Cxcr3 prevents p110\(^{\text{D910A}}\) T cells from fully engaging with the relevant APCs during the early stages of their response to infection. However, the reduced number of Tet+CD8+ Teff did not appear to be caused by altered anatomical redistribution, as we did not find any organ with increased numbers of endogenous Tet+CD8+ T cells in p110\(^{\text{D910A}}\) mice relative to WT mice infected with *L. monocytogenes*.

When we only injected 100 OT1 T cells, we observed comparable expansion of T cells from WT and p110\(^{\text{D910A}}\) donors. Similarly, we also demonstrated in OT1 cotransfer experiments that Ag-specific WT CD8+ T cells can provide help to other responding CD8+ T cells such that the p110\(^{\text{D910A}}\) OT1 T cells expand normally under conditions of cotransfer. Presumably, in both of these cases, there will be an excess of endogenous and/or cotransferred WT OVA-specific T cells also responding to Lm-OVA. Our data and previously published data suggest an endogenous pool of SIINFEKL-specific CD8+ T cells equivalent to 500

**FIGURE 4.** Enhanced bacterial clearance by p110\(^{\text{D910A}}\) mice. (A) WT or p110\(^{\text{D910A}}\) mice were infected with Lm-OVA CFUs recovered from the spleen enumerated at indicated times after infection; \(n = 3–4/\text{group}\), bars show SEM. Statistical analyses: \(p = 0.0002\) by two-way ANOVA. (B and C) Number of CFUs recovered from the spleen (B) or liver (C) 72 h postinfection from a separate experiment from (A) after injection of \(4 \times 10^5\) CFU Lm-OVA. Similar results were obtained from four similar experiments.

**FIGURE 5.** CD8 T cell–intrinsic role for p110\(\delta\) is dose-dependent. The indicated number of purified WT OT1 T cells (CD45.1+) or p110\(^{\text{D910A}}\) OT1 T cells (CD45.2+) were transferred into WT recipient mice (CD45.1+CD45.2+), which were infected 1 d later with Lm-OVA and the number of OT1 T cells and endogenous Tet+CD8+ CD8 T cells in the blood was determined by flow cytometry. The left panel shows number of transferred OT1 T cells recovered from blood samples (filled symbols indicate WT OT1; empty symbols indicate p110\(^{\text{D910A}}\) OT1). The right panel shows endogenous Tet+CD8+ T cells of WT mice receiving WT OT1 T cells (filled symbols) or p110\(^{\text{D910A}}\) OT1 T cells (empty symbols); \(n = 4–8/\text{group}\). Results are representative of two to four independent experiments.
FIGURE 6. T cell–intrinsic and –extrinsic roles for p110δ during primary and secondary responses. (A) Five hundred WT (CD45.1) or p110δD901A (CD45.2) OT1 T cells were transferred into WT hosts (CD45.1 or CD45.2) on day −1. Mice were then infected with Lm-OVA on days 0 and 40. Graphs show the number of OT1 T cells enumerated in the blood following primary and secondary infection by flow cytometry; n = 7–8/group. Filled symbols indicate WT OT1; empty symbols indicate p110δD901A OT1 T cells. Statistical analyses: two-way ANOVA, days 6–10, p = 0.0415; days 45–25, p = 0.0409. Results are representative of three independent experiments. (B) Two hundred fifty WT (CD45.1) and 250 p110δD901A (CD45.2) OT1 T cells were cotransferred into WT hosts (CD45.1/CD45.2) and infected with Lm-OVA the next day and 62 d later. The number of WT and p110δD901A OT1 T cells in the blood is shown. Filled symbols indicate WT OT1 T cells; empty symbols indicate p110δD901A OT1 T cells; n = 8/group. Statistical analyses: two-way ANOVA, days 2–43 and days 66–69 genotypes, not significantly different. Results are representative of three independent experiments. (C) Five hundred WT OT1 T cells (CD45.1) were transferred to either WT (CD45.1/CD45/2) or p110δD901A (CD45.2) mice and infected the following day and then again on day 60 with Lm-OVA. The number of WT OT1 T cells in blood is shown. Filled symbols indicate OT1 cells in WT hosts; empty symbols indicate OT1 cells in p110δD901A hosts; n = 8/group. Statistical analyses: day 1–12, p = 0.0061; days 62–94, not statistically different (two-way ANOVA). (D–F) Number of donor OT1 cells recovered from indicated organs at the peak of the secondary or tertiary responses in repeat experiments, corresponding to (A)–(C). (D) Mice were infected on days 0, 43, and 111 and the number of OT1 T cells in the blood, spleen lymph nodes, and bone marrow was enumerated by flow cytometry at peak tertiary response (day 5 following third infection); n = 7–8/group. Results are representative of two independent experiments. (E) Mice were infected on days 0 and 68 and the number of OT1 T cells in the blood, spleen, lymph node, and bone marrow was enumerated by flow cytometry at peak secondary response (day 5 following second infection); n = 7–8/group. Results are representative of two independent experiments. (F) Mice were infected on days 0 and 52 and the number of WT OT1 T cells in the blood, spleen, lymph nodes, and bone marrow was enumerated by flow cytometry at peak secondary response (day 5 after second infection); n = 8/group. Results are representative of three independent experiments. *p < 0.05 by Student unpaired t test.
transferred OT1 cells. Hence endogenous SIINFEKL-specific CD8+ T cells would exceed transferred p110<sup>dD910A</sup> OT1 cells by a ratio of 5:1 when 100 cells were injected. Similar calculations estimate the ratio of WT to p110<sup>dD910A</sup> to be 3:1 in the cotransfer experiments (500 WT endogenous Tet+CD8+ cells and 250 cotransferred WT OT1 cells against 250 p110<sup>dD910A</sup> OT1 cells). It seems, therefore, that the WT Ag-specific CD8+ T cells need to outnumber the p110<sup>dD910A</sup> T cells by a factor of ∼3:1 or more to provide sufficient signals to support normal expansion of the p110<sup>dD910A</sup> OT1 T cells. We also consider the alternative hypothesis that p110<sup>dD910A</sup> OT1 cells may impede the expansion of cotransferred WT OT1 cells. However, when larger numbers of p110<sup>dD910A</sup> T cells were injected into WT hosts, they did not appear to be more potent than WT OT1 cells at suppressing endogenous responses (which would be expected if p110<sup>dD910A</sup> T cells suppressed the expansion of WT T cells). Hence, we favor the hypothesis that CD8+ T cells responding to the same Ag can support one another to promote optimal proliferation and that their ability to provide such help depends on PI3K<sub>d</sub>.

In addition to the CD8+ T cells themselves, it is likely that PI3K<sub>d</sub> expressed by other cell types also contributes to the production of cytokines and/or costimulatory ligands that promote CD8+ T cell expansion. Thus, when WT OT1 cells were transferred into a p110<sup>dD910A</sup> host, the T cells showed impaired expansion and differentiation when compared with a WT host. We have previously shown that the deletion of Pten within activated CD4+ T cells leads to enhanced Tet+CD8+ T cell responses to Lm-OVA infection (52). CD4 T cells express a number of ligands and cytokines that help facilitate optimal CD8+ T cell responses, and PI3K<sub>d</sub>-deficient T cells produce less IL-2, IFN-γ, IL-21, and CD40L (6, 53–55). It is also possible that PI3K<sub>d</sub>-deficient innate immune cells fail to support optimal CD8+ T cell expansion.

Our studies showed that whereas the Teff response was diminished in p110<sup>dD910A</sup> mice, the production and maintenance of Tmem were largely intact. Administration of a low dose of rapamycin has been shown to enhance the generation of memory T cells following infection (23). Whether the level of inhibition of mTOR in those studies was comparable to that observed when PI3K<sub>d</sub> is inactivated remains to be determined. It is nevertheless interesting that in addition to promoting Tmem, rapamycin is the only drug that has been proven to delay age-related decline in mice (56). We have previously shown that genetic alterations that prolong life by altering PI3K and/or mTOR signaling also preserve the balance of naive

**FIGURE 7.** T cell cytokine and granzyme expression is not dependent on p110<sup>dD910A</sup> in vivo. (A–F) Five hundred WT or p110<sup>dD910A</sup> OT1 T cells were transferred to WT hosts. Mice were infected the next day with Lm-OVA and killed on day 8 postinfection. Proportion of CD44<sup>high</sup> transferred cells in the spleen producing IL-2 (A and B), IFN-γ (C and D), or GzmB (E and F) from mice in which the OT1 cells were transferred into different hosts (A, C, and E) or cotransferred into the same host (B, D, and F). Representative plots are shown to the right of the graphs; n = 5–8/group. No statistically significant differences were found by an unpaired t test. Results are representative of two independent experiments. (G) WT or p110<sup>dD910A</sup> mice on the YETI background were infected with Lm-OVA. Tet+CD8+ T cells harvested from the spleen were analyzed for YFP fluorescence 5 d later. (H) Incorporation of the EdU by Tet+CD8+ T cells 5 d postinfection. (I) Staining with the caspase-binding peptide FAM-VAD-FMK by Tet+CD8+ T cells isolated from spleens 5 d postinfection. **p < 0.01.
T cells to Tmem (which is higher in young mice than in old mice) (57, 58). In this context, it is pertinent to note that although p110D910A mice mounted reduced magnitude CD8+ T cell responses, old p110D910A mice did not show as strong evidence of age-related decline as displayed by the WT mice. Further studies are needed to establish whether PI3Kδ inhibition can delay age-related decline of the immune system.

The results presented in the present study have potential clinical implications. The PI3Kδ inhibitor idelisib is now an approved drug for the treatment of chronic lymphocytic leukemia (59, 60). So far, there is little evidence that PI3Kδ inhibitors increase the risk of infection in these patient populations. The results presented in the present study suggest that, at least in some contexts, PI3Kδ inhibition may in fact help limit bacterial infection. Furthermore, our findings raise the possibility that PI3Kδ inhibitors could be used to augment immune function in the context of certain acute and chronic viral and bacterial infections.

We have recently shown that p110D910A mice are resistant to cancer and that this resistance is dependent on CD8+ T cells (33, 61). The present study may thus form the basis for designing strategies that will favor more robust CD8+ T cell responses while maintaining suppression of regulatory T cell function in the context of PI3Kδ inhibition. Indeed, tumor vaccines, which can in-
29. Fruman, D. A., and G. Bismuth. 2009. Fine tuning the immune response with PI3K. *Immunity* 29: 426–435.

30. Putz, E. M., M. Prechal-Murphy, O. A. Simma, F. Forster, X. Koenig, H. Stockinger, R. P. Piekarz, M. Freissmuth, M. Müller, V. Sexl, and E. Zebedin-Brandl. 2012. PI3Kδ is essential for tumor clearance mediated by cytotoxic T lymphocytes. *PLoS One* 7: e48852.

31. Ali, K. A., Bilancio, M. Thomas, W. Pearce, A. M. Gillilan, C. Tkaczyk, N. Kuehn, A. Gray, J. Giddings, E. Peskett, et al. 2004. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. *Nature* 431: 1007–1011.

32. Deane, J. A., M. G. Kharas, J. S. Oak, L. N. Stiles, J. Luo, T. I. Moore, H. Ji, C. Rommel, L. C. Cantley, T. E. Lane, and D. A. Fruman. 2007. T-cell function is partially maintained in the absence of class Iα phosphoinositide 3-kinase signaling. *Blood* 109: 2894–2902.

33. Ali, K. D. R. Soond, R. Peifer, T. Hagemann, W. Pearce, E. L. Lim, H. Bourau, C. L. Scadmore, T. Hancox, H. Macek, et al. 2014. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. *Nature* 510: 407–411.

34. Pamer, E. G. 2004. Immune responses to *Listeria monocytogenes*. *Nat. Rev. Immunol.* 4: 812–823.

35. Foulds, K. E., L. A. Zenewicz, D. J. Shedlock, J. Jiang, A. E. Troy, and H. Shen. 2002. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. *J. Immunol.* 168: 1528–1532.

36. Pope, C., S. K. Kim, A. Marzo, D. Masopust, K. Williams, J. Jiang, H. Shen, and H. Lefrançois. 2001. Organ-specific regulation of the CD8 T cell response to *Listeria monocytogenes* infection. *J. Immunol.* 169: 3402–3409.

37. Pearce, E. L., and H. Shen. 2007. Generation of CD8 T cell memory is regulated by IL-12. *J. Immunol.* 179: 2074–2081.

38. Patton, D. T., M. D. Wilson, W. C. Rowan, D. R. Soond, and K. Okkenhaug. 2011. The PI3K p110δ regulates expression of CD83 in CD8 T cells. *PLoS One* 6: e17359.

39. Stetson, D. T., M. Dohrs, R. L. Reinhardt, J. L. Baron, Z. E. Wang, L. Gapin, M. Kronenberg, and R. M. Locksley. 2003. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. *J. Exp. Med.* 198: 1069–1076.

40. Okkenhaug, K., A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, and K. Flurkey. 2007. The Mouse in Aging Research. *J. G. Fox, M. T. Davisson, 2nd Ed. J. G. Fox, M. T. Davisson, et al.* 2004. Role of myeloid differentiation factor 88-dependent proinflammatory cytokine signaling. *Proc. Natl. Acad. Sci. USA* 101: 13832–13837.

41. Marchingo, J. M., A. Kan, R. M. Sutherland, K. R. Duffy, C. J. Wellard, G. T. Belz, A. M. Lew, M. R. Dowling, S. Heinzel, and P. D. Hodgkin. 2014. T cell signalling. Antigen affinity, costimulation, and cytokine inputs sum linearly to amplify T cell expansion. *Science* 346: 1123–1127.

42. Soond, D. R., F. Garçon, D. T. Patton, J. Rolli, M. Turner, C. Scadmore, O. A. Garden, and K. Okkenhaug. 2012. Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. *J. Immunol.* 188: 5935–5943.

43. Rolli, J. S., E. Bell, D. Kovesdi, M. L. Janas, D. R. Soond, L. M. Webb, S. Santinelli, T. Saunders, B. Hebeis, N. Killeen, et al. 2010. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. *J. Immunol.* 185: 4042–4052.

44. Okkenhaug, K., D. T. Patton, A. Bilancio, F. Garçon, W. C. Rowan, and B. Vanhaesebroeck. 2006. The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. *J. Immunol.* 177: 5122–5128.

45. Liu, D., T. Zhang, A. J. Marshall, K. Okkenhaug, B. Vanhaesebroeck, and J. E. Uozuma. 2009. The p110δ isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. *J. Immunol.* 183: 1921–1933.

46. Harrison, D. E., R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle, K. Flurkey, N. L. Nadon, J. E. Wilkinson, K. Frenkel, C. S. Carter, et al. 2009. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 460: 392–395.

47. Selman, C., L. J. Tandy, G. J. O’Shea, S. P. Schoenberger, M. Clements, F. Ramadani, K. Okkenhaug, E. Schuster, E. Blanc, et al. 2008. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. *FASEB J.* 22: 807–818.

48. Selman, C., J. M. Tlutel, D. Wieser, E. Irvine, S. J. Lingard, A. I. Choudhury, M. Claret, H. Al-Qassab, D. Carmignac, F. Ramadani, et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. *Science* 326: 140–144.

49. Fruman, R. R., J. P. Sharman, S. E. Coutre, B. D. Cheson, J. M. Pagel, P. Hillmen, J. C. Barrientos, A. D. Zelenetz, T. J. Kipps, I. Flinn, et al. 2014. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N. Engl. J. Med.* 370: 997–1007.

50. Gopal, A. K., B. S. Kahl, S. de Vos, N. D. Wagner-Johnston, S. J. Schuster, W. J. Jarzack, I. W. Flinn, C. R. Flowers, P. Martin, A. Viardot, et al. 2014. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N. Engl. J. Med.* 370: 1008–1018.

51. Dussel, J. M., C. M. Huber, K. Okkenhaug, and F. Colucci. 2015. Immuno-modulation of selective naive T cell functions by p110δ inactivation promotes the outcome of mismatched cell transplantation. *Cell Rep.* 10: 702–710.

52. Brockstedt, D. G., M. A. Ginell, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky, Jr. 2004. *Listeria*-based cancer vaccines that segregate immunogenicity from toxicity. *Proc. Natl. Acad. Sci. USA* 101: 13832–13837.

53. Angulo, I., O. Vadás, F. Garçon, E. Banham-Hall, V. Plagnol, T. R. Leathy, H. Baxendale, T. Couter, J. Curtis, C. Wu, et al. 2013. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. *Science* 342: 866–871.

54. Lucas, C. L., H. S. Kuehn, F. Zhao, J. E. Niemela, E. K. Deenick, U. Palendira, D. T. Avery, L. Moens, J. L. Cannons, M. Biancalana, et al. 2014. Dominant-activating germline mutations in the gene encoding the PI3K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. *Nat. Immunol.* 15: 88–97.